FULCRUM THERAPEUTICS, INC.
26 Landsdowne Street
Cambridge, MA 02139
VIA EDGAR
April 24, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Fulcrum Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-3
Filed February 27, 2024
File No. 333-277419
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Fulcrum Therapeutics, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to April 25, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134.
| Fulcrum Therapeutics, Inc. |
| /s/ Alan Musso |
| Alan Musso |
cc: Alan Musso, Fulcrum Therapeutics, Inc.
Curt Oltmans, Fulcrum Therapeutics, Inc.
Mitchell Bloom, Goodwin Procter LLP
Marianne Sarrazin, Goodwin Procter LLP